Therapy for Wilson’s disease ‘shows promise’
Phase three trial has met its primary endpoint, pharmaceutical company says
An experimental drug to treat Wilson’s disease has achieved its primary endpoint in a phase three trial, AstraZeneca reports.
The pharmaceutical company said its medicine for the rare genetic disease that causes accumulation of copper in the body was three times more successful in helping remove deposits from tissues than standard care.
